[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 172, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sven Ante Lundberg M.D.", "age": 60, "title": "CEO, President & Executive Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1114527, "exercisedValue": 0, "unexercisedValue": 10252539}, {"maxAge": 1, "name": "Mr. Gregory D. Perry", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 419102, "exercisedValue": 0, "unexercisedValue": 801494}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 45, "title": "EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 781842, "exercisedValue": 565022, "unexercisedValue": 1331558}, {"maxAge": 1, "name": "Dr. Andrew  Joe M.D.", "age": 57, "title": "Consultant", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 685115, "exercisedValue": 0, "unexercisedValue": 1537678}, {"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Harry  Shuman", "title": "Chief Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 58, "title": "CTO & Executive VP", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 362037, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kathleen  Farren", "title": "IR & Corporate Communications Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander Berthold Hendrik Bakker Ph.D.", "age": 57, "title": "Executive VP, Chief Development Officer & Head of Merus Utrecht", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 410076, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 51.74, "open": 51.7, "dayLow": 51.54, "dayHigh": 52.74, "regularMarketPreviousClose": 51.74, "regularMarketOpen": 51.7, "regularMarketDayLow": 51.54, "regularMarketDayHigh": 52.74, "beta": 1.114, "forwardPE": -14.435616, "volume": 266027, "regularMarketVolume": 266027, "averageVolume": 503775, "averageVolume10days": 552810, "averageDailyVolume10Day": 552810, "marketCap": 3594010880, "fiftyTwoWeekLow": 19.805, "fiftyTwoWeekHigh": 61.61, "priceToSalesTrailing12Months": 102.12289, "fiftyDayAverage": 50.9858, "twoHundredDayAverage": 47.67285, "currency": "USD", "enterpriseValue": 2817607168, "floatShares": 62644504, "sharesOutstanding": 68210496, "sharesShort": 8889186, "sharesShortPriorMonth": 6634912, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1303, "heldPercentInsiders": 0.02037, "heldPercentInstitutions": 1.01851, "shortRatio": 15.85, "shortPercentOfFloat": 0.1311, "bookValue": 11.006, "priceToBook": 4.787389, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -167663008, "trailingEps": -2.89, "forwardEps": -3.65, "pegRatio": 1.97, "enterpriseToRevenue": 80.062, "enterpriseToEbitda": -14.481, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "42321671-9233-3f73-a2ee-487472589127", "gmtOffSetMilliseconds": -14400000, "currentPrice": 52.69, "targetHighPrice": 111.0, "targetLowPrice": 67.0, "targetMeanPrice": 89.0, "targetMedianPrice": 88.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 787422976, "totalCashPerShare": 11.544, "ebitda": -194568992, "totalDebt": 11020000, "quickRatio": 9.786, "currentRatio": 9.974, "totalRevenue": 35193000, "debtToEquity": 1.476, "revenuePerShare": 0.608, "returnOnAssets": -0.19617, "returnOnEquity": -0.33393002, "freeCashflow": -77823128, "operatingCashflow": -102633000, "revenueGrowth": -0.3, "operatingMargins": -8.77987, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]